Stephen Poor
Head, Translational Medicine Apellis Pharmaceuticals
Physician scientist (UK trained ophthalmologist) with over 20 years drug discovery and development experience.
Current role is Head of Translational Medicine at Apellis. Broad responsibilities include clinical trial leadership for GA and Alzheimer’s programs, BD&L, end-point strategy, clinical trial optimization and technology innovation.
Previous roles @ Novartis include Head of Retinal Pharmacology, Director External Innovation and Global Program Clinical Head for Ophthalmology.
Seminars
Thursday 10th December 2026
Deepening Understanding of Complement Biology in Ophthalmology to Enable Targeted Intervention & Improve Patient Outcomes
12:30 pm
- Investigating the role of complement dysregulation across ophthalmologic diseases and its contribution to disease onset, progression and vision loss
- Identifying biomarkers that could predict disease development, patient risk and treatment response to support earlier intervention strategies
- Elucidating relevant targets within the complement cascade that offer the greatest therapeutic potential within ocular diseases
